S Le Guyader-Peyrou1, A Belot2, M Maynadié3, F Binder-Foucard4, L Remontet5, X Troussard6, N Bossard5, A Monnereau7. 1. Réseau français des registres des cancers, Francim, 31073 Toulouse, France; Registre des hémopathies malignes de la Gironde, institut Bergonié, 33076 Bordeaux, France. Electronic address: s.leguyaderpeyrou@bordeaux.unicancer.fr. 2. Service de biostatistique, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69424 Lyon, France; Université de Lyon, 69000 Lyon, France; Université Lyon I, 69622 Villeurbanne, France; CNRS, UMR5558, laboratoire de biométrie et biologie évolutive, équipe biostatistique-santé, 69100 Villeurbanne, France; Département des maladies chroniques et traumatismes, institut de veille sanitaire, 94410 Saint-Maurice, France. 3. EA4184, registre des hémopathies malignes de Côte d'Or, université de Bourgogne, 21078 Dijon, France. 4. EA 3430, registre des cancers du Bas-Rhin, laboratoire d'épidémiologie et de santé publique, faculté de médecine, université de Strasbourg, 67085 Strasbourg cedex, France; Service de santé publique, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France. 5. Service de biostatistique, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69424 Lyon, France; Université de Lyon, 69000 Lyon, France; Université Lyon I, 69622 Villeurbanne, France; CNRS, UMR5558, laboratoire de biométrie et biologie évolutive, équipe biostatistique-santé, 69100 Villeurbanne, France. 6. Registre des hémopathies malignes de Basse Normandie, 14033 Caen, France; Laboratoire d'hématologie, CHU de Caen, 14033 Caen, France. 7. Registre des hémopathies malignes de la Gironde, institut Bergonié, 33076 Bordeaux, France; Inserm, centre de recherche U1219, équipe EPICENE (epidemiology of cancer and environmental exposure), ISPED, 33000 Bordeaux, France.
Abstract
BACKGROUND: The classification of hematological malignancies (HMs) has changed in recent decades. For the first time, the French network of cancer registries (Francim) provides estimates for incidence and trends of HM in France between 1980 and 2012 for major HM subtypes. METHODS: Incidence was directly estimated by modeling the incidence rates measured in the cancer registry area. For each HM subtype, a "usable incidence period" was defined a priori, corresponding to the years for which all the registries collected them in a homogeneous way. For both sexes and each HM subtype, age-period-cohort models were used to estimate national incidence trends. RESULTS: Overall in France, there were an estimated 35,000 new HMs in 2012 (19,400 in men and 15,600 in women). Lymphoid malignancies accounted for more than two-thirds of HM incident cases (n=25,136). The incidence sex ratio (M/F) varied from 1.1 for classical Hodgkin lymphoma to 4.0 for mantle-cell lymphoma. The median age at diagnosis ranged from 62 to 81 years according to the major HM subtypes. Overall in both sexes, the top five most frequent HMs in 2012 were plasma cell neoplasm (about 4900 estimated cases), chronic lymphocytic leukemia/small lymphocytic lymphoma (4500 cases), diffuse large B-cell lymphoma and myelodysplastic syndromes (4100 cases), and acute myeloid leukemia (2800 cases). The incidence rates increased for follicular lymphoma and plasma cell neoplasm during the study period in both sexes. Classical Hodgkin lymphoma was relatively stable in men between 1980 and 2012 and increased in both sexes during the most recent period. Chronic myeloproliferative neoplasms, other than chronic myelogenous leukemia, are the only subtype that showed a slightly downward trend in incidence between 2003 and 2012 in both sexes. CONCLUSION: The striking differences in the incidence patterns by histologic subtype strongly suggest a certain level of etiologic heterogeneity among hematological malignancies and support the pursuit of epidemiologic analysis by subtype for HMs in international studies. Age-standardized incidence rates are essential to analyze trends in risk, whereas the number of incident cases is necessary to make provisions for healthcare resources and to evaluate the overall burden of HM.
BACKGROUND: The classification of hematological malignancies (HMs) has changed in recent decades. For the first time, the French network of cancer registries (Francim) provides estimates for incidence and trends of HM in France between 1980 and 2012 for major HM subtypes. METHODS: Incidence was directly estimated by modeling the incidence rates measured in the cancer registry area. For each HM subtype, a "usable incidence period" was defined a priori, corresponding to the years for which all the registries collected them in a homogeneous way. For both sexes and each HM subtype, age-period-cohort models were used to estimate national incidence trends. RESULTS: Overall in France, there were an estimated 35,000 new HMs in 2012 (19,400 in men and 15,600 in women). Lymphoid malignancies accounted for more than two-thirds of HM incident cases (n=25,136). The incidence sex ratio (M/F) varied from 1.1 for classical Hodgkin lymphoma to 4.0 for mantle-cell lymphoma. The median age at diagnosis ranged from 62 to 81 years according to the major HM subtypes. Overall in both sexes, the top five most frequent HMs in 2012 were plasma cell neoplasm (about 4900 estimated cases), chronic lymphocytic leukemia/small lymphocytic lymphoma (4500 cases), diffuse large B-cell lymphoma and myelodysplastic syndromes (4100 cases), and acute myeloid leukemia (2800 cases). The incidence rates increased for follicular lymphoma and plasma cell neoplasm during the study period in both sexes. Classical Hodgkin lymphoma was relatively stable in men between 1980 and 2012 and increased in both sexes during the most recent period. Chronic myeloproliferative neoplasms, other than chronic myelogenous leukemia, are the only subtype that showed a slightly downward trend in incidence between 2003 and 2012 in both sexes. CONCLUSION: The striking differences in the incidence patterns by histologic subtype strongly suggest a certain level of etiologic heterogeneity among hematological malignancies and support the pursuit of epidemiologic analysis by subtype for HMs in international studies. Age-standardized incidence rates are essential to analyze trends in risk, whereas the number of incident cases is necessary to make provisions for healthcare resources and to evaluate the overall burden of HM.
Authors: Stéphanie Foulon; Pascale Cony-Makhoul; Agnès Guerci-Bresler; Marc Delord; Eric Solary; Alain Monnereau; Julia Bonastre; Pascale Tubert-Bitter Journal: Cancer Med Date: 2019-04-30 Impact factor: 4.452